Feeds

Cutting cancer rates: Data, models and a happy ending?

How surgery might be making cancer prognoses worse

In theory, the definitive treatment for early stage cancer patients should be surgical resection. Just get in there and cut the tumour out. If the lump is small and well-constrained, then surgical removal is all that should be needed. Unfortunately, this isn’t usually what happens.

Even when the tumour is nice and small and easily got at, patients mostly have to go through the rigours of chemotherapy and/or radiotherapy and all the traumas that these treatments entail. Why? Because for many types of cancer, surgery is often followed by relapse – the disease pops up again, usually somewhere else in the body, even though all traces of it appear to have been removed.

In breast cancer, for example, the pattern of relapse is very clear. When looking at patient data we can see there’s a peak of relapse in the first two to four years, then there’s a lull and then a smaller wave of relapses much later on.

This bimodal relapse pattern occurs not just in breast cancer, but prostate, lung, pancreatic, melanoma and osteosarcoma. And in case any of you data nerds were wondering, this bimodal pattern seems to be pretty robust across different data sets, and appears to be independent of disease stage or other prognostic factors.

All of which begs the question of why cancers should behave this way. The standard model of cancer has assumed that there’s an exponential growth pattern when tumours are small, but then this rate of growth slows as they get bigger – technically, it’s a damped exponential.

If we can treat cancers by cutting them out, why do we need chemotherapy?

So, for a long time the working hypothesis is that even when tumours are small there are already microscopic pockets of disease hiding in the body, and when the primary tumour is cut out these microscopic metastases carry on growing. As they are very small the model says they should be growing very fast, so then you need to whack them with chemotherapy – which is basically a poison targeted at rapidly growing cells. Hence the need to follow surgery with chemo…

However, the problem is that this model suggests that relapse should be related to disease staging. The bigger your tumour, the longer it’s been around, the longer the micrometastases have been growing; hence the faster the relapse. But that’s not what the data says. The data says that it’s the surgical intervention that’s acting as the trigger mechanism.

A number of researchers and doctors (including Michael Retsky, Romano Demicheli, Michael Baum, William Hrushesky, Isaac Gukas and others) across the globe puzzled over this discrepancy when it first became apparent in the 1990s. They worked together to figure out what was going on and to try and tease out a better model of cancer growth. A model which could be used not just to explain the data but, more importantly, to see what could be done in terms of changing therapies.

And this is the key point, this isn’t just an arcane data science or computer modelling issue, it’s not about understanding the molecular biology of cancer, it’s about making a significant impact on treatment. Because it’s not the primary tumour that kills most patients, it’s metastatic disease spreading through the body.

Surgery might not be the answer in every single case

In time a new model has been developed, and rather than tumour dynamics being described by a damped exponential equation, it turned out to be intermittent and dynamically non-random. And in the case of breast cancer, most relapses are the result of a sudden spurt of metastatic growth that is triggered by the surgery itself. In other words, the treatment that should be most curative is kicking off a process that leads to cancer relapse within four years.

Now, funnily enough, this isn’t necessarily a new finding. It turns out that historically doctors in ancient Greece and Rome had also noticed that surgery to remove breast cancers could make things much worse. It also fits in with folk wisdom in certain parts of the world – for example in Africa many women presenting with cancer do not go to conventional oncologists because they fear that surgery would “provoke” the disease.

So, why should surgery have this effect? It turns out that there are probably multiple effects at work. Firstly, surgery itself causes a massive release of chemicals into the bloodstream that signals to the body that there’s been tissue damage and that it needs to repair itself.

This repair includes the sprouting of new blood vessels (a process called angiogenesis) at the site of the wound. Unfortunately, these same factors in the blood also help tiny pockets of cancer cells sprout the blood supply they need to get the nutrients and oxygen to grow.

At the same time the surgery induces a drop in the immune system – so where tiny cancers have been kept in check by the immune system, they are suddenly let off the leash as the body recovers from surgery. The surgery itself may also release tumour cells into the bloodstream, cells that can circulate and find a welcoming home somewhere else in the body.

Whitepapers

Why and how to choose the right cloud vendor
The benefits of cloud-based storage in your processes. Eliminate onsite, disk-based backup and archiving in favor of cloud-based data protection.
Getting started with customer-focused identity management
Learn why identity is a fundamental requirement to digital growth, and how without it there is no way to identify and engage customers in a meaningful way.
High Performance for All
While HPC is not new, it has traditionally been seen as a specialist area – is it now geared up to meet more mainstream requirements?
Getting ahead of the compliance curve
Learn about new services that make it easy to discover and manage certificates across the enterprise and how to get ahead of the compliance curve.
Intelligent flash storage arrays
Tegile Intelligent Storage Arrays with IntelliFlash helps IT boost storage utilization and effciency while delivering unmatched storage savings and performance.